4.8 Article

Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank

期刊

MOLECULAR PSYCHIATRY
卷 27, 期 2, 页码 1248-1255

出版社

SPRINGERNATURE
DOI: 10.1038/s41380-021-01344-2

关键词

-

资金

  1. University of Manchester Presidential Fellowship [P123958]
  2. UK Research and Innovation Future Leaders Fellowship [MR/T021780/1]
  3. National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre
  4. NIHR Advanced Fellowship [NIHR301206]
  5. UKRI [MR/T021780/1] Funding Source: UKRI
  6. National Institutes of Health Research (NIHR) [NIHR301206] Funding Source: National Institutes of Health Research (NIHR)

向作者/读者索取更多资源

People with severe mental illness, including schizophrenia/psychosis and bipolar disorder, have higher risks of COVID-19 infection, hospitalisation, and mortality. These disparities were not fully accounted for by demographic characteristics or comorbidities. Prioritizing vaccination and preventive measures for these vulnerable groups is important.
People with severe mental illness (SMI; including schizophrenia/psychosis, bipolar disorder (BD), major depressive disorder (MDD)) experience large disparities in physical health. Emerging evidence suggests this group experiences higher risks of infection and death from COVID-19, although the full extent of these disparities are not yet established. We investigated COVID-19 related infection, hospitalisation and mortality among people with SMI in the UK Biobank (UKB) cohort study. Overall, 447,296 participants from UKB (schizophrenia/psychosis = 1925, BD = 1483 and MDD = 41,448, non-SMI = 402,440) were linked with healthcare and death records. Multivariable logistic regression analysis was used to examine differences in COVID-19 outcomes by diagnosis, controlling for sociodemographic factors and comorbidities. In unadjusted analyses, higher odds of COVID-19 mortality were seen among people with schizophrenia/psychosis (odds ratio [OR] 4.84, 95% confidence interval [CI] 3.00-7.34), BD (OR 3.76, 95% CI 2.00-6.35), and MDD (OR 1.99, 95% CI 1.69-2.33) compared to people with no SMI. Higher odds of infection and hospitalisation were also seen across all SMI groups, particularly among people with schizophrenia/psychosis (OR 1.61, 95% CI 1.32-1.96; OR 3.47, 95% CI 2.47-4.72) and BD (OR 1.48, 95% CI 1.16-1.85; OR 3.31, 95% CI 2.22-4.73). In fully adjusted models, mortality and hospitalisation odds remained significantly higher among all SMI groups, though infection odds remained significantly higher only for MDD. People with schizophrenia/psychosis, BD and MDD have higher risks of COVID-19 infection, hospitalisation and mortality. Only a proportion of these disparities were accounted for by pre-existing demographic characteristics or comorbidities. Vaccination and preventive measures should be prioritised in these particularly vulnerable groups.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据